Sclerostin in CKD-MBD: One more paradoxical bone protein?

Nephrology Dialysis Transplantation

Volumn 28, Issue 12, 2013, Pages 2932-2935

  Jean, Guillaume ^a   Chazot, Charles ^a  

^a NEPHROCARE Tassin Charcot ^*  (France)

Author keywords

Bone disease; Bone marker; Kidney disease; Sclerostin; Survival

Indexed keywords

ALKALINE PHOSPHATASE; CALCITONIN; ESTROGEN; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; SCLEROSTIN;

ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE DISEASE; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE MARKER; HEMODIALYSIS; HUMAN; HYPEROSTOSIS; IMMOBILIZATION; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOSCLEROSIS; PRIORITY JOURNAL; SENESCENCE; SURVIVAL RATE; WNT SIGNALING PATHWAY;

BONE DISEASE; BONE MARKER; KIDNEY DISEASE; SCLEROSTIN; SURVIVAL;

BONE DISEASES, METABOLIC; BONE MORPHOGENETIC PROTEINS; GENETIC MARKERS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84890011563     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft222     Document Type: Article

References (34)

1. KDIGO C-M, Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone disorder (CKD-MBD). Kidney Int 2009; 76: S1-130
2. Asci G, Ok E, Savas R et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant 2011; 26: 1010-1015
3. Hofbauer LC, Brueck CC, Shanahan CM et al. Vascular calcification and osteoporosis-from clinical observation towards molecular understanding. Osteoporos Int 2007; 18: 251-259
4. Sigrist MK, Levin A, Er L et al. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009; 24: 3157-3162
5. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796
6. Kovesdy CP, Ureche V, Lu JL et al. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010; 9: 3003-3011
7. Robling AG, Niziolek PJ, Baldridge LA et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008; 283: 5866-5875
8. Ott SM. Sclerostin and Wnt signaling-the pathway to bone strength. J Clin Endocrinol Metab 2005; 90: 6741-6743
9. Brunkow ME, Gardner JC, Van Ness J et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68: 577-589
10. Bellido T. Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact 2006; 6: 358-359
11. Yu EW, Kumbhani R, Siwila-Sackman E et al. Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab 2011; 96: E1848-E1851
12. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 234-241
13. Urano T, Shiraki M, Ouchi Y et al. Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women. J Clin Endocrinol Metab 2012; 97: E1473-7
14. Garnero P, Sornay-Rendu E, Munoz F et al. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2013; 24: 489-494
15. Spatz JM, Fields EE, Yu EW et al. Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab 2012; 97: E1736-E1740
16. Szulc P, Bertholon C, Borel O et al. Lower fracture risk in older men with higher sclerostin concentration-a prospective analysis from the MINOS study. J Bone Miner Res 2013; 28: 855-864
17. Ardawi MS, Rouzi AA, Al-Sibiani SA et al. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research study. J Bone Miner Res 2012; 27: 2592-2602
18. Tian X, Setterberg RB, Li X et al. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 2010; 47: 529-533
19. van Lierop AH, Witteveen JE, Hamdy NA et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010; 163: 833-837
20. Polyzos SA, Anastasilakis AD, Bratengeier C et al. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int 2012; 23: 1171-1176
21. Chung YE, Lee SH, Lee SY et al. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int 2012; 23: 1235-1243
22. Thambiah S, Roplekar R, Manghat P et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90: 473-480
23. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011; 6: 877-882
24. Cejka D, Jager-Lansky A, Kieweg H et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226-230
25. Zhu D, Mackenzie NC, Millan JL et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011; 6: e19595
26. Askevold ET, Gullestad L, Aakhus S et al. Secreted wnt modulators in symptomatic aortic stenosis. J Am Heart Assoc 2012; 1: e002261
27. Shalhoub V, Ward SC, Sun B et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int 2011; 89: 140-150
28. Jean G, Bresson E, Terrat JC et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948-955
29. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
30. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122: 2543-2553
31. Ketteler M, Biggar PH, Liangos O. FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant 2012; 28: 821-825.
32. Morena M, Terrier N, Jaussent I et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006; 17: 262-270
33. Jabbar S, Drury J, Fordham JN et al. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol 2011; 64: 354-357
34. Shin S, Kim KJ, Chang HJ et al. Impact of serum calcium and phosphate on coronary atherosclerosis detected by cardiac computed tomography. Eur Heart J 2012; 33: 2873-2881